{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:02Z","timestamp":1792790342735,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Swedish Cancer Society","award":["CF240906"],"award-info":[{"award-number":["CF240906"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","award":["FoUI-988468"],"award-info":[{"award-number":["FoUI-988468"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Swedish Research Council","award":["2024-06358"],"award-info":[{"award-number":["2024-06358"]}]},{"name":"The Swedish Blood Cancer Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>FLT3-<\/jats:italic>\n                    mutated acute myeloid leukemia (AML) is associated with high relapse rates and treatment resistance. Triplet therapy with azacitidine (AZA), venetoclax (VEN), and the FLT3 inhibitor gilteritinib (GILT) yields high response rates but is limited by myelosuppression and infections. We conducted a multicenter retrospective study of 29\n                    <jats:italic>FLT3<\/jats:italic>\n                    -mutated AML patients treated with GILT-triplets. The primary endpoint was overall survival (OS); secondary endpoints event-free survival (EFS) and time to neutrophil and platelet recovery. Patients received one of three regimens: concomitant triplet therapy (Group 1); concomitant AZA\u2009+\u2009VEN followed by concomitant VEN+GILT (Group 2); or overlapping AZA\u2009+\u2009VEN followed by GILT monotherapy (Group 3). For the entire cohort median OS was not reached after more than five years of follow-up. High response rates were observed across all schedules. Limiting concomitant exposure reduced myelosuppression and decreased infectious complications compared with full triplet therapy. Median OS was not reached in Groups 1 and 2 after three years, whereas Group 3 had a median OS of 18 months. Median EFS was 40.5 months in Group 1 and was not reached at five years in Group 2, compared with 11.5 months in Group 3. Our data suggest that reducing the duration of triple-drug overlap may improve tolerability without compromising clinical outcomes.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07297-2","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:35:00Z","timestamp":1792733700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed\/refractory AML"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9971-880X","authenticated-orcid":false,"given":"Matilda","family":"Arvidsson Kvissberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-0050","authenticated-orcid":false,"given":"Christer","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-6507","authenticated-orcid":false,"given":"Niklas","family":"Landberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-7299","authenticated-orcid":false,"given":"Albin","family":"\u00d6sterroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristea","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8996-2612","authenticated-orcid":false,"given":"Bertil","family":"Uggla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-4423","authenticated-orcid":false,"given":"Vladimir","family":"Lazarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1888-5567","authenticated-orcid":false,"given":"Stefan","family":"Deneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-3235","authenticated-orcid":false,"given":"Martin","family":"J\u00e4dersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"7297_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S et al (2010) Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34:752\u2013756. https:\/\/doi.org\/10.1016\/j.leukres.2009.10.001","journal-title":"Leuk Res"},{"key":"7297_CR2","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/BLOOD-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776\u20132784. https:\/\/doi.org\/10.1182\/BLOOD-2007-08-109090","journal-title":"Blood"},{"key":"7297_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/BLOOD.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/BLOOD.2019003988","journal-title":"Blood"},{"key":"7297_CR4","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/BLOOD.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA et al (2022) Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139:3366. https:\/\/doi.org\/10.1182\/BLOOD.2021011583","journal-title":"Blood"},{"key":"7297_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/nejmoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3 -Mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/nejmoa1902688","journal-title":"N Engl J Med"},{"key":"7297_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/AJH.26447","volume":"97","author":"Y Numan","year":"2022","unstructured":"Numan Y, Abdel Rahman Z, Grenet J et al (2022) Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol 97:322\u2013328. https:\/\/doi.org\/10.1002\/AJH.26447","journal-title":"Am J Hematol"},{"key":"7297_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/S41375-022-01742-7","volume":"37","author":"PY Dumas","year":"2022","unstructured":"Dumas PY, Raffoux E, B\u00e9rard E et al (2022) Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO. Leukemia 37:91\u2013101. https:\/\/doi.org\/10.1038\/S41375-022-01742-7","journal-title":"Leukemia"},{"key":"7297_CR8","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/S41375-024-02382-9","volume":"38","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang B, Li J et al (2024) Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia 38:2410\u20132418. https:\/\/doi.org\/10.1038\/S41375-024-02382-9","journal-title":"Leukemia"},{"key":"7297_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/BLOOD-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/BLOOD-2018-08-868752","journal-title":"Blood"},{"key":"7297_CR10","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly, Joseph et al (2022) Venetoclax plus Gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol 40:4048\u20134059","journal-title":"J Clin Oncol"},{"key":"7297_CR11","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/AJH.25146","volume":"93","author":"B Chyla","year":"2018","unstructured":"Chyla B, Daver N, Doyle K et al (2018) Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am J Hematol 93:E202\u2013E205. https:\/\/doi.org\/10.1002\/AJH.25146","journal-title":"Am J Hematol"},{"key":"7297_CR12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD et al (2024) Azacitidine, venetoclax, and Gilteritinib in newly diagnosed and relapsed or refractory FLT3 -Mutated AML. J Clin Oncol 42:1499\u20131508. https:\/\/doi.org\/10.1200\/JCO.23.01911","journal-title":"J Clin Oncol"},{"key":"7297_CR13","doi-asserted-by":"publisher","unstructured":"Fu Q, Wang Y, Liu H et al (2024) Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3mut acute myeloid leukemia. Leuk Res 145. https:\/\/doi.org\/10.1016\/j.leukres.2024.107564","DOI":"10.1016\/j.leukres.2024.107564"},{"key":"7297_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/BLOOD.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/BLOOD.2022016867","journal-title":"Blood"},{"key":"7297_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/S41408-025-01429-Z;SUBJMETA","author":"W-Y Jen","year":"2025","unstructured":"Jen W-Y, Lachowiez CA, Marvin-Peek J et al (2025) Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide. Blood Cancer J. https:\/\/doi.org\/10.1038\/S41408-025-01429-Z;SUBJMETA","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07297-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:01:44Z","timestamp":1792782104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7297"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07297-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"479"}}